Scientists uncover a molecular weakness that could transform prostate cancer therapy. An international team of researchers has identified a new weakness in prostate cancer cells that could enhance ...
Celcuity Inc. ((CELC)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced ...
GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate ...
The National Institute for Health and Care Excellence (NICE) has recommended darolutamide in combination with androgen ...
GSK shares lifted on Monday after the pharmaceutical giant signed a £268m deal with French biotech Syndivia for a potential treatment for prostate cancer.
NICE recommends Bayer’s Nubeqa® (darolutamide) plus androgen deprivation therapy as a treatment option for patients with hormone-sensitive metastatic prostate cancer Nubeqa® (darolutamide) plus ...
GSK said it acquired exclusive worldwide rights for a drug candidate targeting prostate cancer from France's Syndivia for up to 268 million pounds ($356.8 million).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback